Inter-placental variability is not a major factor affecting the healing efficiency of amniotic membrane when used for treating chronic non-healing wounds

Abstract

This study aimed to evaluate the efficacy of cryopreserved amniotic membrane (AM) grafts in chronic wound healing, including the mean percentage of wound closure per one AM application, and to determine whether the healing efficiency differs between AM grafts obtained from different placentas. A retrospective study analyzing inter-placental differences in healing capacity and mean wound closure after the application of 96 AM grafts prepared from nine placentas. Only the placentas from which the AM grafts were applied to patients suffering from long-lasting non-healing wounds successfully healed by AM treatment were included. The data from the rapidly progressing wound-closure phase (p-phase) were analyzed. The mean efficiency for each placenta, expressed as an average of wound area reduction (%) seven days after the AM application (baseline, 100%), was calculated from at least 10 applications. No statistical difference between the nine placentas’ efficiency was found in the progressive phase of wound healing. The 7-day average wound reduction in particular placentas varied from 5.70 to 20.99% (median from 1.07 to 17.75) of the baseline. The mean percentage of wound surface reduction of all analyzed defects one week after the application of cryopreserved AM graft was 12.17 ± 20.12% (average ± SD). No significant difference in healing capacity was observed between the nine placentas. The data suggest that if there are intra- and inter-placental differences in AM sheets’ healing efficacy, they are overridden by the actual health status of the subject or even the status of its individual wounds.

Outcome of Application of Cryopreserved Amniotic Membrane Grafts in the Treatment of Chronic Nonhealing Wounds of Different Origins in Polymorbid Patients: A Prospective Multicenter Study

“…), and last but not least the AM application frequency [ 46 , 47 ]. Also, it was documented that the individual sensitivity to the AM but not the inter or intra-placental differences are predominant in the efficiency of AM treatment [ 34 ].…”

“…AM was decontaminated by antibiotic solution (Base 128, Alchimia, s.r.l., Ponte San Nicolò, Padova, Italy), then minimally processed (cleaned from blood clots) and cryopreserved (−80 °C) in a mixture of Dulbecco’s Modified Eagle’s Medium (DMEM, c.n. 32430-027, Gibco Life Technologies, Invitrogen, Waltham, MA, USA) and glycerol (Glycerolum 85%, Dr. Kulich Pharma s.r.o., Hradec Kralove, Czech Republic) 1:1 [ 34 ]. During tissue processing and packaging, sterility tests were performed.…”